N-[5-(7-cyclopropyl-2,6-dioxo-3-propylpurin-8-yl)pyridin-2-yl]-N-ethylpyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-[5-(7-cyclopropyl-2,6-dioxo-3-propylpurin-8-yl)pyridin-2-yl]-N-ethylpyridine-3-carboxamide
• 化学式: C₂₄H₂₅N₇O₃
• 分子量: 459.5
• InChiKey: ZTXGSUVLBXCMES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS)<br/>[FR] RÉDUCTION DE DIABÈTE CHEZ DES PATIENTS RECEVANT DES INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)
  申请人：JOLLA INST ALLERGY IMMUNOLOG

  公开号：WO2014153424A1

  公开（公告）日：2014-09-25

  The invention provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking a statin. The invention also provides compositions, methods and uses for reducing or decreasing increases in blood glucose caused by a statin in a subject taking a statin. The invention further provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking statins, and for treating diabetes in a subject taking statins. The invention moreover provides compositions, including an adenosine receptor antagonist, and/or an A2B receptor antagonist, and/or a CD73 antagonist and a statin.